Navigation Links
Discovery of an anti-inflammatory substance
Date:11/8/2010

This release is available in German.

The messenger interleukin-27 plays an important role when the human body blocks inflammations. This was discovered by an international research team, of which the Kiel Professors Joachim Grtzinger and Stefan Rose-John, as well as the doctoral candidate, Bjrn Spudy, are a part of. The research findings of the scientists from Kiel, the US and Great Britain were published yesterday, Sunday (7 November 2010), in the online advance edition of Nature Immunology.

The human immune system reacts to bodily injuries and infections with inflammation. This is important for the healing process, but can result in harmful effects if it becomes chronic. Inflammation is triggered by messengers such as the cytokine interleukin-6 (IL-6). This peptide hormone latches on to special receptor molecules on cells and compels inflammation. "We observed that another cytokine, interleukin-27, can counteract this effect", explained Professor Joachim Grtzinger, from the Institute of Biochemistry at Kiel University. "IL-27 latches on to the same receptors as IL-6 and thus inhibits the inflammatory reaction." The Kiel biochemists were able to support the international research team with their knowledge of IL-6 in particular. According to Grtzinger, "We have dedicated ourselves to this topic for over 20 years". Professor Stefan Rose-John added: "We hope that these fundamental findings will one day be able to aid the healing of chronic inflammatory diseases".

The Christian-Albrechts-Universitt zu Kiel (CAU) has proven international expertise as a North German research university in the field of Life Sciences. This fact is emphasised by the cluster of excellence Inflammation at Interfaces, with which the CAU was successful in the first round of the national Excellence Initiative, together with the University of Lbeck and the Research Center Borstel. The Collaborative Research Centre (CRC) 877, "Proteolysis as a Regulatory Event in Pathophysiology", whose spokesperson is Rose-John and in which Grtzinger is also involved, substantiates the competence of Kiel in the field of Life Sciences as well. CRC 877 deals with signalling pathways within and between cells, which are triggered by the fission of proteins.


'/>"/>

Contact: Dr. Joachim Groetzinger
jgroetzinger@biochem.uni-kiel.de
49-431-880-1686
Kiel University
Source:Eurekalert

Related biology news :

1. Chemical equator discovery will aid pollution mapping
2. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
3. Groundbreaking discovery may lead to stronger antibiotics
4. Discovery of natural compounds that could slow blood vessel growth
5. Nanoscopic screening process to speed drug discovery
6. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
7. New $11 million center to speed production of new compounds for drug discovery
8. Discovery of giant roaming deep sea protist provides new perspective on animal evolution
9. New discovery may enhance MRI scans, lead to portable MRI machines
10. Kidney function discovery sheds light on genetic complexity of disease
11. Discovery of new gene associated with diabetes risk suggests link with body clock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/14/2016)... CLARA, Calif. , Nov. 14, 2016 ... the biometric identification market, Frost & Sullivan ... Frost & Sullivan Award for Visionary Innovation ... player in the biometric identification market by ... multi-modal verification solution for instant, seamless, and ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... the FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, ... require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits ...
(Date:12/8/2016)... Frederick, Maryland (PRWEB) , ... ... ... Inc announces the commercial launch of flexible packaging for their exceptionally ... (“SU”) disposable bag system extends RoosterBio’s portfolio of bioprocess media products engineered ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented today ... clinical trial for its lead drug candidate, AC0010, at the World Conference on ... to determine the safety, antitumor activity, and recommended phase II dosage of AC0010 ...
Breaking Biology Technology: